Must-read for patients: Dosage and usage of avatrombopag/Sucoxin

Avatrombopag, a thrombopoietin receptor agonist, is a drug used in certain conditions that cause thrombocytopenia (low platelets), such as thrombocytopenia associated with chronic liver disease (CLD), in adult patients undergoing planned medical or dental procedures. Avatrombopag is available as 20 mg tablets, and its dosage includes the following:

For patients with chronic liver disease (CLD) and thrombocytopenia (ITP), avatropopag may be started 10 to 13 days before planned surgery. The recommended daily dose is based on the patient's platelet count before the scheduled procedure. Patients should undergo surgery 5 to 8 days after the last dose of avatropopag. Patients need to take it orally once a day for 5 consecutive days with food. For patients with a platelet count of less than 40×10^9/L, the dosage is 60 mg (3 tablets) once a day, and for patients with a platelet count of 40-50×10^9/L, the dosage is 40 mg (2 tablets) once a day. In the event of a missed dose, the patient should take the next dose as soon as he or she remembers. Patients should not take two doses at once to make up for a missed dose, but should take the next dose at the usual time the next day; all 5 days of dosing should be completed.

For thrombocytopenia in patients with chronic immune thrombocytopenia (ITP): Use the lowest dose of avatrombopag as needed to achieve and maintain a platelet count ≥50×10^9/L, thus reducing the risk of bleeding. Dose adjustments are based on platelet count response. Do not use avatrombopag to normalize platelet counts. The initial dosage regimen is to start with a starting dose of 20 mg (1 tablet), taken once a day with food.